Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2012

View Archived Issues

Phase II safety and immunogenicity data presented for West Nile vaccine

GLYX-13 has antidepressant activity without psychotomimetic effects

Plexxikon presents phase II results for PLX-3397

Enrollment completed in second phase III tedizolid phosphate trial

Inovio Pharmaceuticals reports interim data from its DNA-based flu vaccine study

Portola Pharmaceuticals begins phase II study of PRT-4445

Biotie's phase IIb tozadenant study meets endpoints

Autism Speaks awards grant to Seaside Therapeutics

Administration complete in seasonal flu vaccine phase III trial

Myriad to perform protein biomarker discovery under diabetes collaboration

OncoTherapy Science provides update on COMPETE-PC study

ONO-4059 demonstrates inhibition of arthritis severity and bone damage in vivo

German scientists disclose novel antibodies binding to claudin-6

MilleGen and INSERM prepare new human antibodies for cancer

New agents for obesity presented by Zafgen

New NS5B inhibitors patented by Bristol-Myers Squibb

Teva Pharmaceutical licenses Xenon's pain drug

Merck & Co. divulges new SYK inhibitors

FDA expands indication for Zytiga

BG Medicine obtains CE Mark for CardioSCORE test

Phase III trial of arbaclofen ER tablets for spasticity due to MS begins

Interferon alpha-2b XL shows activity similar to peginterferon alfa-2b

Phase I trial of 4SC's anticancer compound achieves all primary objectives

AstraZeneca and Isis Pharmaceuticals enter strategic alliance for cancer

Oncomatrix and University of Stuttgart form partnership

Mediator of muscle atrophy in critically ill patients identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...